By Stephen Fink and Anupam Jena (July 17, 2020, 6:11 PM EDT) -- In January, the state of California enacted its new legislation, A.B. 824, making reverse payment patent settlements associated with Hatch-Waxman Act pharmaceutical litigation — or pay-for-delay settlements — presumptively anti-competitive.
This law, which has been subject to legal challenges and is currently being appealed with oral arguments taking place earlier this month, differs from existing legal antitrust precedent established by a number of federal court cases as well as Federal Trade Commission enforcement policies. This includes the U.S. Supreme Court's ruling in FTC v. Actavis which established that a rule-of-reason analysis is to be used rather than assuming that "reverse payment...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!